Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Not Recruiting

Trial ID: NCT04267120


This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal carcinoma who have not received any chemotherapy for advanced disease.

Official Title

A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Stanford Investigator(s)

Alice C. Fan
Alice C. Fan

Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Locally advanced or metastatic histologically confirmed nccRCC (2, 7). Must have one
   of the following subtypes of nccRCC:

      - papillary RCC

      - chromophobe RCC

      - TFE-3/B translocation RCC

      - SDHB-loss RCC

      - TSC1-loss RCC

      - sarcomatoid RCC without clear cell component

      - unclassified RCC

   - Has not received any prior lines of systemic therapy except adjuvant or neoadjuvant

   - Radiologically measurable disease meeting the following criteria:

      - At least 1 lesion of ≥ 10 mm in the longest diameter for a non-lymph node or ≥ 15
      mm in the short axis diameter for a lymph node which is serially measurable
      according to iRECIST (Section 12) using computerized tomography (CT) or magnetic
      resonance imaging (MRI).

      - Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies
      such as radiofrequency (RF) ablation must show evidence of subsequent progressive
      disease (substantial size increase of ≥20%) to be deemed a target lesion.
      Patients who received EBRT must be at least 2 weeks out from last RT treatment.

   - At least 18 years of age.

   - Karnofsky performance status ≥ 70%

   - Blood pressure (BP) ≤ 150/90 mmHg at screening with or without antihypertensive
   medications and no change in antihypertensive medications within 1 week prior to Cycle
   1 Day 1.

   - Adequate renal function defined as creatinine <1.5 x ULN or calculated creatinine
   clearance ≥40 mL/min per the Cockcroft and Gault formula with creatinine levels >1.5 x

   - Adequate bone marrow function:

      - Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 x 103/L)

      - Platelets ≥100,000/mm3 (≥100 x 109/L)

      - Hemoglobin ≥9.0 g/dL

   - Adequate blood coagulation function as evidenced by an International Normalized Ratio
   (INR) ≤1.5

   - Adequate liver function as evidenced by:

      - bilirubin ≤1.5 times the upper limit of normal (ULN)

      - alkaline phosphatase (ALP) ≤3×ULN (in the case of liver metastases ≤5×ULN)

      - alanine aminotransferase (ALT) ≤3×ULN (in the case of liver metastases ≤5×ULN)

      - aspartate aminotransferase (AST) ≤3×ULN (in the case of liver metastases ≤5×ULN).

In case ALP is >3×ULN (in the absence of liver metastases) or >5×ULN (in the presence of
liver metastases) AND the subject also is known to have bone metastases, the liver specific
ALP isoenzyme must be separated from the total and used to assess the liver function
instead of the total ALP.

   - Subjects with known brain metastases will be eligible if they have completed the
   primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery, or
   complete surgical resection) and if they have remained clinically stable,
   asymptomatic, and off steroids for at least 2 months before starting study treatment.

   - All females of childbearing potential must have a negative serum or urine pregnancy
   test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic
   gonadotropin [β-hCG]) at the screening visit. Females of childbearing potential* must
   agree to use a highly effective method of contraception for the entire study period
   and for 120 days after study discontinuation

   - Male subjects who are partners of women of childbearing potential must follow one of
   the methods of contraception described in Section 6.5 beginning at least 1 menstrual
   cycle prior to starting study drugs, throughout the entire study period, and for 120
   days after the last dose of study drug, unless the male subjects are totally sexually
   abstinent or have undergone a successful vasectomy with confirmed azoospermia or
   unless the female partners have been sterilized surgically or are otherwise proven

   - Archival tumor tissue from within 3 months (preferred) or up to 6 months (acceptable)
   must be available prior to the first dose of study drug for biomarker analysis. If no
   biopsy has been performed in the prior 6 months, a standard of care biopsy is
   requested if safe and feasible. In the case tissue cannot be provided, patients can be
   enrolled upon consultation and agreement by the trial PI.

Note: In case of submitting unstained cut slides, freshly cut slides should be submitted to
the testing laboratory within 14 days from when the slides are cut.

-Ability to understand and willingness to sign an IRB approved written informed consent
document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

   - Predominant clear cell renal cell carcinoma (RCC)

   - Uncontrolled or untreated brain metastasis

   - Major surgery performed within 4 weeks prior to the first dose of study drugs or
   scheduled for major surgery during the study. Subjects must have recovered adequately
   from any toxicity and/or complications from major surgery prior to starting therapy.

   - Subjects having >1+ proteinuria on urinalysis will undergo 24-h urine collection for
   quantitative assessment of proteinuria. Subjects with urine protein ≥1 g/24-hour will
   be ineligible.

   - Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition
   that might affect the absorption of lenvatinib.

   - New York Heart Association congestive heart failure of grade II or above, unstable
   angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia
   associated with significant cardiovascular impairment within the past 6 months.

   - Prolongation of QTc interval to >480 msec.

   - Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to
   the first dose of study drug.

   - Active infection (any infection requiring systemic treatment).

   - Subject is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B,
   or Hepatitis C

   - Serious nonhealing wound, ulcer, or bone fracture.

   - Known intolerance to either of the study drugs (or any of the excipients).

   - History of organ allograft (subject has had an allogenic tissue/solid organ
   transplant) or allogeneic stem cell transplant (subject has received blood-forming
   stem cells from a donor).

   - Biologic response modifiers (e.g., granulocyte colony-stimulating factor) within 4
   weeks before study entry. Chronic erythropoietin therapy is permitted provided that no
   dose adjustments were made within 2 months before first dose of study treatment.

   - Any medical or other condition which, in the opinion of the investigator, would
   preclude participation in a clinical trial.

   - Is pregnant or breastfeeding, or expecting to conceive or father children within the
   projected duration of the trial, starting with the pre-screening or screening visit
   through 120 days after the last dose of trial treatment. If the required urine
   pregnancy test is positive (or cannot be confirmed as negative) within 72 hours prior
   to start of treatment, a serum pregnancy test will be required.

   - Excluding the primary tumor leading to enrollment in this study, any other active
   malignancy (except for definitively treated melanoma in-situ, basal or squamous cell
   carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past
   36 months.

   - Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
   other form of immunosuppressive therapy within 7 days prior to the first dose of study
   treatment. The use of up to 10 mg/day of prednisone or equivalent is approved and does
   not exclude the patient from the trial.

   - Active autoimmune disease that has required systemic treatment in past 2 years (i.e.,
   with use of disease modifying agents, > 10 mg of prednisone per day, or
   immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
   physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
   etc.) is not considered a form of systemic treatment. The use of up to 10 mg/day of
   prednisone or equivalent is approved and does not exclude the patient from the trial.

   - Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
   maintenance steroids (>10 mg of prednisone) or current pneumonitis/interstitial lung

   - Has received a live-virus vaccination or live-attenuated vaccine within 30 days of
   planned treatment start. Administration of killed vaccines is allowed.


drug: Lenvatinib

drug: Pembrolizumab

procedure: Research blood collection

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Noel Del Toro

New Trial Alerts